Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)

OBJECTIVES: Assess golimumab's long-term efficacy/safety in psoriatic arthritis (PsA). METHODS: Adults with active PsA (≥3 swollen and tender joints, active psoriasis) were randomly assigned to subcutaneous placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks (q4wks) through wk20. All pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanaugh, Arthur, McInnes, Iain B, Mease, Philip, Krueger, Gerald G, Gladman, Dafna, van der Heijde, Désirée, Zhou, Yiying, Lu, Jiandong, Leu, Jocelyn H, Goldstein, Neil, Beutler, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145441/
https://www.ncbi.nlm.nih.gov/pubmed/24748630
http://dx.doi.org/10.1136/annrheumdis-2013-204902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145441/
https://www.ncbi.nlm.nih.gov/pubmed/24748630
http://dx.doi.org/10.1136/annrheumdis-2013-204902

Ejemplares similares